...
首页> 外文期刊>Neuroepidemiology >Survival of Patients with Amyotrophic Lateral Sclerosis in a Population-Based Registry.
【24h】

Survival of Patients with Amyotrophic Lateral Sclerosis in a Population-Based Registry.

机译:肌萎缩性侧索硬化患者在基于人群的登记中的生存。

获取原文
获取原文并翻译 | 示例

摘要

Objective: To evaluate the survival of patients with amyotrophic lateral sclerosis (ALS) in an Italian population and to assess the effects of selected prognostic indicators on survival. Background: Median survival of ALS patients has been reported to range between 12 and 23 months from diagnosis and between 23 and 36 months from onset of symptoms. Although several negative prognostic factors have been identified, the overall picture still needs clarification. Methods: We included patients enrolled in an Italian ALS Regional Register (population 4,529,003) during the calendar year 1998. The diagnosis was confirmed by an ad hoc committee using the original El Escorial criteria. Each case was regularly followed up until death or December 31, 2002, whichever came first. Survival was assessed with the Kaplan-Meier method in the whole sample, by level of diagnostic certainty, and by selected prognostic indicators (age, sex, bulbar or spinal onset, and disease duration). Multivariate analysis was done with the Cox proportional hazard function. Results: The sample comprised 79 patients (33 female; 46 male) aged 28-85 years (mean age 64.4 years). Onset of symptoms was bulbar in 30% of cases. Mean symptom duration at diagnosis was 13.3 months. ALS was definite in 43%, probable in 29%, possible in 6%, and suspected in 22%. By December 31, 2002, 56 cases (71%) had died. The cumulative probability of surviving after diagnosis was 78% at 12 months, 56% at 24 months, and 32% at 48 months. Median survival from onset was 39.2 months and from diagnosis 30.6 months. Multivariate analysis confirmed definite ALS at diagnosis and older age as adverse prognostic factors. Conclusions: Survival of ALS patients in the present sample was slightly longer than previously reported. Better palliative care and supportive treatment may explain the difference. Older age and the presence of definite ALS at diagnosis are poor prognostic predictors. Copyright (c) 2005 S. Karger AG, Basel.
机译:目的:评估意大利人群中肌萎缩性侧索硬化症(ALS)患者的生存率,并评估所选的预后指标对生存率的影响。背景:据报道,ALS患者的中位生存期从诊断开始为12至23个月,从症状发作为23至36个月。尽管已经确定了几个负面的预后因素,但总体情况仍需要澄清。方法:我们纳入了1998历年意大利ALS地区登记册(人口4,529,003)中登记的患者。诊断由特设委员会使用原始的Escorial标准进行确认。每例均接受定期随访,直至死亡或2002年12月31日,以较早者为准。使用Kaplan-Meier方法评估整个样本的生存率,诊断确定性水平以及所选的预后指标(年龄,性别,延髓或脊髓发作以及疾病持续时间)。使用Cox比例风险函数进行了多变量分析。结果:该样本包括79位患者(33位女性; 46位男性),年龄28-85岁(平均年龄64.4岁)。在30%的病例中,症状发作为延髓。诊断时平均症状持续时间为13.3个月。 ALS的确定性为43%,大概为29%,可能为6%,怀疑为22%。截至2002年12月31日,已有56例病例(71%)死亡。诊断后存活的累积概率在12个月时为78%,在24个月时为56%,在48个月时为32%。发病的中位生存期为39.2个月,诊断为30.6个月。多因素分析证实诊断明确和年龄较大的ALS是不良预后因素。结论:本样本中ALS患者的生存期比以前报道的稍长。更好的姑息治疗和支持治疗可以解释这种差异。年龄大和在诊断时存在明确的ALS是不良的预后预测指标。版权所有(c)2005 S.Karger AG,巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号